Results 191 to 200 of about 245,202 (346)

Efficacy and tolerability of fenfluramine with concomitant potassium bromide in patients with Dravet syndrome

open access: yesEpilepsia Open, EarlyView.
Abstract Objective To assess the efficacy and tolerability of fenfluramine (FFA) with concomitant potassium bromide (BR) in patients with Dravet syndrome (DS). Methods This multicenter retrospective study, conducted within the German compassionate use program, analyzed BR doses and serum levels before and after FFA initiation, adverse events (AEs ...
Milka Pringsheim   +13 more
wiley   +1 more source

Neurochemical studies on GABA receptor: I.3H-Muscimol binding in rat brain

open access: gold, 1979
Yukio Yoneda   +2 more
openalex   +1 more source

Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases. [PDF]

open access: bronze, 1982
Hiroo Kuroda   +6 more
openalex   +1 more source

SCN1A gain of function effects in Dravet syndrome: Insights into clinical phenotypes and therapeutic implications

open access: yesEpilepsia Open, EarlyView.
Abstract A large number of cases with Dravet syndrome (DS) has been attributed to SCN1A loss of function (LOF), whereas SCN1A gain‐of‐function (GOF) causes early infantile developmental and epileptic encephalopathy (EIDEE) and familial hemiplegic migraine 3.
Yoko Kobayashi Takahashi   +13 more
wiley   +1 more source

Exploring the long‐term effects of COVID‐19 in patients with epilepsy: A multicenter Italian observational study

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Coronavirus disease‐19 (COVID‐19), caused by SARS‐CoV‐2, has led to a global pandemic since December 2019. People with epilepsy (PwE) face higher risks of severe COVID‐19 outcomes and may be more vulnerable to long‐term neurological and psychiatric effects. Methods This multicenter, retrospective cohort study reviewed medical records
Fedele Dono   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy